Mark Schoenberg - 31 Jan 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Jan 2024
Net transactions value
-$59,639
Form type
4
Filing time
02 Feb 2024, 19:07:36 UTC
Previous filing
08 Sep 2023
Next filing
20 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +2,000 +1.3% 150,560 31 Jan 2024 Direct F1
transaction URGN Ordinary Shares Sale $17,896 -1,137 -0.76% $15.74 149,423 31 Jan 2024 Direct F2
transaction URGN Ordinary Shares Options Exercise +1,333 +0.89% 150,756 31 Jan 2024 Direct F1
transaction URGN Ordinary Shares Sale $11,931 -758 -0.5% $15.74 149,998 31 Jan 2024 Direct F2
transaction URGN Ordinary Shares Options Exercise +3,333 +2.2% 153,331 31 Jan 2024 Direct F1
transaction URGN Ordinary Shares Sale $29,812 -1,894 -1.2% $15.74 151,437 31 Jan 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -2,000 -100% $0.000000* 0 31 Jan 2024 Ordinary Shares 2,000 Direct F1, F3
transaction URGN Restricted Stock Units Options Exercise $0 -1,333 -50% $0.000000 1,334 31 Jan 2024 Ordinary Shares 1,333 Direct F1, F4
transaction URGN Restricted Stock Units Options Exercise $0 -3,333 -33% $0.000000 6,667 31 Jan 2024 Ordinary Shares 3,333 Direct F1, F5
transaction URGN Restricted Stock Units Award $0 +10,000 $0.000000 10,000 31 Jan 2024 Ordinary Shares 10,000 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
F4 The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
F5 The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
F6 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027.